EFFICACY OF EARLY GLARGINE PLUS STANDARD IV INSULIN VERSUS STANDARD IV INSULIN IN PATIENTS WITH DIABETIC KETOACIDOSIS: A RANDOMISED CONTROLLED TRIAL - NIL

Start Date30 Sep 2024

Sponsor / Collaborator-

NCT06340854 / Active, not recruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes

This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec once a week, or one injection of insulin glargine once a day, depending on the treatment group participants are assigned into. Participants will use a pen with a small needle to inject the medicine under participants skin into participants thigh, upper arm or stomach.The study will last for about 9 months, but participants will only be taking the study medicine for 6 months.

Start Date19 Apr 2024

Sponsor / Collaborator

Novo Nordisk A/S

NCT06619301 / RecruitingPhase 3IIT

Randomized Controlled Trial of Glargine Versus Neutral Protamine Hagedorn Insulin for the Treatment of Diabetes Mellitus in Pregnancy

We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy. Currently, many hospitals differ among use of insulin for management of DM in pregnancy, with NPH, glargine and detemir being the most commonly used forms of basal insulin. Outside of pregnancy, NPH is rarely used with glargine and determir being the more common forms of insulin used due to their fewer episodes of hypoglycemia in these patients. Detemir has been well studied in pregnancy and found to be noninferior to NPH. Unfortunately, glargine has not been as well studied in pregnancy. Thus, with this study we want to compare glargine and NPH.
The purpose of this study is to compare two different forms of insulin (Glargine and NPH) that we regularly use to manage diabetes mellitus in pregnancy.

Start Date01 Apr 2024

Sponsor / Collaborator

Loyola University Medical Center

100 Clinical Results associated with Insulin glargine (Sanofi)

100 Translational Medicine associated with Insulin glargine (Sanofi)

100 Patents (Medical) associated with Insulin glargine (Sanofi)

2,136

Literatures (Medical) associated with Insulin glargine (Sanofi)

01 Jan 2025·DIABETES OBESITY & METABOLISM

Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis

Article

Author: Gourdy, Pierre ; Vera, Carine ; Mauquoi, Celine ; Müller‐Wieland, Dirk ; Mauricio, Didac ; Bonnemaire, Mireille ; Bonadonna, Riccardo C. ; Freemantle, Nick

Abstract:

Aim:

To evaluate the effectiveness and safety of insulin glargine 300 U/mL (Gla‐300) initiation according to diabetes duration (DD).

Materials and Methods:

We analysed patient‐level data from 2381 insulin‐naïve individuals with type 2 diabetes (T2D), of whom 2349 (98.7%) were treated with Gla‐300 for 24 weeks. Of the 2381 participants, 1048 (44.0%) had a DD of less than 8 years and 1333 (56.0%) had a DD of 8 years or longer. We further analysed the subgroups of participants having a DD of less than 4 years (N = 450), 4‐8 years (N = 598), 8‐12 years (N = 627) and 12 years or longer (N = 706).

Results:

Mean ± standard deviation age was 60.2 ± 9.0 years in participants with a DD less than 8 years and 64.2 ± 8.8 years in those with a DD of 8 years or longer. At 24 weeks of Gla‐300 therapy, HbA1c improved with a least‐squares (LS) mean change from baseline of −1.88% (95% confidence interval [CI], −1.95 to −1.80) and −1.71% (95% CI, −1.77 to −1.65), respectively, resulting in a LS mean difference between groups of 0.17% (95% CI, 0.07 to 0.26; P = .0005). In the subgroup analysis, LS mean HbA1c reduction from baseline to week 24 was highest in participants with a DD of less than 4 years and lowest in participants with a DD of 12 years or longer. Overall, incidences of symptomatic and severe hypoglycaemia were low, irrespective of DD, without body weight changes.

Conclusions:

Gla‐300 was effective and safe in insulin‐naïve individuals with T2D, regardless of DD. Improvement in HbA1c was greater when Gla‐300 was initiated in participants with a DD of less than 4 years, although the difference between the groups was modest.

01 Dec 2024·Indian journal of pediatrics

Beyond HbA1c: Identifying Gaps in Glycemic Control Among Children and Young People with Type 1 Diabetes Using Continuous Glucose Monitoring

Article

Author: Bhatia, Vijayalakshmi ; Bhowmik, Eshita ; Tripathi, Sarita ; Ali, Zebish ; Dabadghao, Preeti ; Bk, Ajitha ; Sudhanshu, Siddhnath ; Tandon, Ambica

OBJECTIVES:

To describe continuous glucose monitoring (CGM) derived glycemic variables, and study their association with HbA1c and socio-economic factors in young people with Type 1 diabetes mellitus (T1DM).

METHODS:

Ninety-two participants [age 15.7 ± 5.0 y (mean ± SD), HbA1c 8.0 ± 1.5% (mean ± SD)] wore a professional CGM sensor for 14 d.

RESULTS:

Median (IQR) time in range (TIR) was 41 (18)%. Participants spent 41 ± 20% of their day in hyperglycemia (>180 mg/dl), and 14 (13)% in hypoglycemia (<70 mg/dl). High glycemic variability (percent CV >36%) was seen in 92% participants. Older age at diagnosis was associated with higher TIR (β = 0.267, p = 0.01), lower time above range (TAR) (β = -0.352, p <0.001), but higher time below range (TBR) (β = 0.274, p = 0.006). The use of NPH vs. glargine basal insulin was associated with higher TBR (β = -0.262, p = 0.009) but lower TAR (β = 0.202, p = 0.041). HbA1c showed negative correlation with TIR (r = -0.449, p <0.001) and TBR (r = -0.466, p <0.001) and positive correlation with TAR (r = 0.580, p <0.001) and mean glucose (r = 0.589, p <0.001).

CONCLUSIONS:

These data demonstrate wide gaps between the recommended vs. real world glycemic variables in patients with T1DM in this region on multiple daily insulin injections. CGM identifies glycemic variability and complements HbA1c in improving glycemic control.

01 Dec 2024·DIABETES CARE

One-Year Thermostability of Commercial Glargine and Human Insulin

Letter

Author: Garrett, Timothy J. ; Christopher, Michael W. ; Lee, Jae Hwan ; Bazargani, Sina Feizbakhsh ; Haller, Michael J. ; Veigle, Olivia ; Atkinson, Philip M. ; Mcgrail, Sean ; Lloyd, Sierra ; Atkinson, Mark A.

104

News (Medical) associated with Insulin glargine (Sanofi)

12 Nov 2024

·pipelinereview.com

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

BEIJING, China I November 12, 2024 I Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the positive topline results of a Phase 1 clinical trial its oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) GZR18 tablets in healthy participants in China. Statement: The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants, designed to assess the bioavailability, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GZR18 tablets in healthy adult participants. The study also evaluated the effect of meal timing on the drug’s PK, PD, safety, and tolerability. In this study, GZR18 tablets were safe and well-tolerated, with the most common adverse events being gastrointestinal reactions, consistent with the established safety profile of GLP-1 based therapies. PK data indicated favorable absorption, supporting a once-daily oral regimen. Both single and multiple doses showed a dose-response relationship in terms of PK and PD parameters. Participants treated with the target dose of 60 mg daily for two weeks exhibited an average weight reduction of 4.16% from baseline. Furthermore, a week after stopping treatment, subjects continued to lose weight 0.51%, reaching an average total reduction of 4.67% compared to baseline. At 21 days after discontinuation, neither the participants’ body weight nor BMI had returned to baseline values. About GZR18 Tablets GZR18 tablet is an investigational, once-daily oral GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals. It utilizes a small molecule absorption enhancer, SNAC (N-[8-(2-hydroxybenzoyl)amino] caprylate), to facilitate drug absorption in the stomach by resisting pepsin degradation, thus prolonging the drug’s half-life and enhancing its bioavailability. GZR18 tablets are currently in global Phase 1 clinical development. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ® ), fast-acting lispro injection (Prandilin ™ ), fast-acting aspart injection (Rapilin ® ), mixed protamine zinc lispro injection (25R) (Prandilin ™ 25), aspart 30 injection (Rapilin ® 30), and one human insulin injection – mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ® ). In China’s 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ® ) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. SOURCE: Gan & Lee Pharmaceuticals

Phase 1Drug ApprovalClinical Result

12 Nov 2024

·www.prnewswire.com

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1 receptor agonists, with no unexpected safety signals during the study. BEIJING, Nov. 12, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the positive topline results of a Phase 1 clinical trial its oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) GZR18 tablets in healthy participants in China. Statement: GZR18 tablet is an ivestigational drug and has not yet been approved in China. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants, designed to assess the bioavailability, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GZR18 tablets in healthy adult participants. The study also evaluated the effect of meal timing on the drug's PK, PD, safety, and tolerability. In this study, GZR18 tablets were safe and well-tolerated, with the most common adverse events being gastrointestinal reactions, consistent with the established safety profile of GLP-1 based therapies. PK data indicated favorable absorption, supporting a once-daily oral regimen. Both single and multiple doses showed a dose-response relationship in terms of PK and PD parameters. Participants treated with the target dose of 60 mg daily for two weeks exhibited an average weight reduction of 4.16% from baseline. Furthermore, a week after stopping treatment, subjects continued to lose weight 0.51%, reaching an average total reduction of 4.67% compared to baseline. At 21 days after discontinuation, neither the participants' body weight nor BMI had returned to baseline values. About GZR18 Tablets GZR18 tablet is an investigational, once-daily oral GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals. It utilizes a small molecule absorption enhancer, SNAC (N-[8-(2-hydroxybenzoyl)amino] caprylate), to facilitate drug absorption in the stomach by resisting pepsin degradation, thus prolonging the drug's half-life and enhancing its bioavailability. GZR18 tablets are currently in global Phase 1 clinical development. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. SOURCE Gan & Lee Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Clinical ResultDrug Approval

11 Nov 2024

·www.prnewswire.com

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0.99%; and at 30 weeks, participants' body weight continued to decrease. The clinical efficacy and safety of bi-weekly 48 mg and once-weekly 24 mg GZR18 injections were comparable, with no significant difference in mean percent change in body weight from baseline between the two groups (one-sided test, P > 0.025). GZR18 injections were safe and well tolerated, with the most commonly reported adverse events being gastrointestinal reactions, comparable to similar drugs. BEIJING, Nov. 11, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the results of the Phase 2b clinical study of GZR18 injection, a bi-weekly (twice a month) glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by the company, in adult overweight/obese patients in China were presented as an oral presentation at ObesityWeek®️ 2024. Statement: GZR18 is an investigational drug and is not approved for use in any country. Gan & Lee Pharmaceuticals does not endorse the use of any unapproved drug or indication. The Phase 2b clinical trial (CTR20231695) was a multicenter, randomized, double-blind, placebo-controlled, dose-finding study designed to evaluate the efficacy and safety of bi-weekly (Q2W) and once-weekly (QW) dosing regimens of GZR18 injection. The study enrolled a total of 340 participants, all of whom were obese (BMI≥28 kg/m²) or overweight (BMI≥24 kg/m²) with at least one weight-related comorbidity and whose weight was poorly controlled by diet and exercise. Participants were randomly assigned to receive 12 mg (n=52), 18 mg (n=53), 24 mg (n=52), 48 mg (n=64) GZR18 injections bi-weekly, or 24 mg (n=53) once-weekly GZR18 injection, or placebo (n=66) for 30 weeks (including a dose escalation period). The primary efficacy endpoint was the percentage change in body weight from baseline after 30 weeks of treatment. The study results showed a significant reduction in body weight from baseline at week 30 in participants receiving different doses and dosing frequencies of GZR18 injection, with weight loss not yet reaching a plateau. In the Q2W GZR18 dose groups, participants experienced dose-dependent weight loss: 11.15% (1.04) in the 12 mg group, 13.22% (0.95) in the 18 mg group, 14.25% (1.01) in the 24 mg group, and 17.29% (0.99) in the 48 mg group. In the QW 24 mg group, participants experienced a weight reduction of 17.78% (1.01), while the placebo group showed only a -0.99% (0.91) change. Moreover, there was no significant difference in efficacy between the 48 mg Q2W and 24 mg QW groups (one-sided test P>0.025). In the 48 mg Q2W GZR18 group, the proportions of participants achieving ≥5%, 10%, and 20% weight loss were 97.8%, 82.2%, and 37.8%, respectively. GZR18 injection was safe and well tolerated, with the most common adverse events being mild to moderate gastrointestinal reactions. No serious adverse events were reported in any treatment group. *Trial data are presented as mean (standard error). The detailed results of the Phase 2b study of GZR18 Injection will be published in a peer-reviewed journal. Dr. Zhong-ru Gan, Chairman of Gan & Lee Pharmaceuticals, commented: "The results of this Phase 2b study further validate the excellent performance of GZR18 injection in weight management, particularly with the bi-weekly dosing regimen, which has shown comparable efficacy to the once-weekly regimen. The bi-weekly formulation of GLP-1 has the potential to enhance patient adherence, thereby improving long-term weight management outcomes. GZR18 injection, as the first single-target GLP-1 biweekly formulation, clinical data has demonstrated weight loss effects comparable to or even better than multi-target GLP-1 once-weekly formulations, providing new insights for the future development of GLP-1 drugs. The development of the bi-weekly GZR18 injection is expected to offer more flexible treatment options for patients with obesity, and we look forward to further validating these findings in the upcoming Phase 3 clinical trials." Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. SOURCE Gan & Lee Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2Drug ApprovalPhase 3

100 Deals associated with Insulin glargine (Sanofi)

External Link

KEGG	Wiki	ATC	Drug Bank
D03250	Insulin glargine (Sanofi)	A10AE04	DB00047

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus	EU	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	IS	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	LI	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus	NO	Sanofi-Aventis Deutschland GmbH	09 Jun 2000
Diabetes Mellitus, Type 1	US	Sanofi-Aventis U.S. LLC	20 Apr 2000
Diabetes Mellitus, Type 2	US	Sanofi-Aventis U.S. LLC	20 Apr 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	US	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	AR	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	BR	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	CA	Sanofi	01 Apr 2008
Acute myocardial infarction	Phase 3	MX	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	US	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	AR	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	BR	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	CA	Sanofi	01 Apr 2008
Diabetic Coma	Phase 3	MX	Sanofi	01 Apr 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Diabetes Mellitus, Type 2	568	甘精胰岛素U300 (初治)	pafsebaexn(ntanjqvlrw) = dzlzlutlbe vnowjgxupm (pzzxntkplj ) View more	Positive	19 Nov 2024
				甘精胰岛素U300 (基础胰岛素转换)	pafsebaexn(ntanjqvlrw) = yzgugsmowe vnowjgxupm (pzzxntkplj ) View more
ISN WCN2024	Not Applicable	Diabetes Mellitus, Type 2 \| Kidney Failure, Chronic	11	NPH insulin	kouafjsalt(qjmixxqgjb) = zulpjgiksk owkcfmpnjn (kjpgtvlyjc, ±76.9)	Positive	01 Apr 2024
				Glargine insulin	kouafjsalt(qjmixxqgjb) = agcwnmglaf owkcfmpnjn (kjpgtvlyjc, ±60.6)
NCT03703869 (Pubmed \| Diabetes Ther)	Not Applicable	Diabetes Mellitus, Type 2	412	Insulin Glargine U300 (Gla-300)	yoqtjjdbmx(hdirhiasoi) = PROs improved xqjdnhfyqs (jhqggnyoyw ) View more	Positive	01 Mar 2024
EASD2023	Not Applicable	Diabetes Mellitus, Type 2	-	Insulin glargine 300 U/mL (Gla-300)	uticsczhia(ffmqmfztri) = luntqzghjf dctrliecdt (oieapbjlzp )	-	05 Oct 2023
				Long-acting basal insulins (BIs)/NPH insulin	uticsczhia(ffmqmfztri) = zajujudfok dctrliecdt (oieapbjlzp )
ORIGIN (ESC2023)	Not Applicable	Sex hormone-binding globulin (SHBG) \| testosterone	-	Glargine	mnhnctiwyq(bisfcuhezg) = pykhxbccle mjbabwvezl (njlpowunff )	-	26 Aug 2023
				Glargine	mnhnctiwyq(bisfcuhezg) = uliiqbbrug mjbabwvezl (njlpowunff )
NCT03874715 (GEMELLI X, CTgov)	Phase 3	Diabetes Mellitus, Type 1	210	Insulin glargine U100+Insulin Aspart SAR341402 (Switching: NovoLog/SAR341402)	jchoxgbulq(fnadjduuvv) = lgcyqzssip jujmfxvuar (rwciknxffe, wwkjdouwse - ixbxqoybei) View more	-	21 Jul 2023
				Insulin glargine U100+Insulin Aspart (Non-switching: NovoLog)	jchoxgbulq(fnadjduuvv) = sibxegbyqx jujmfxvuar (rwciknxffe, kjasbewshj - rzptugcfhl) View more
RESTORE-G (ADA2023)	Not Applicable	-	-	Glargine 300 U/mL	yocdvnfokj(ookhfslkhv) = fzswchdfkf hjtnudvcci (kyymllgems )	-	23 Jun 2023
ADA2023	Not Applicable	-	-	Bridging dose of G with first dose of D	olobusraym(zukubximja) = qaipcgzuad nkehwzsdup (kxfppaljhx )	-	20 Jun 2023
				Placebo	havlwzgvff(wpworanqmq) = efyhfygwyo hpnomjajtd (jviksbsiio )
GRADE (ASN2022)	Not Applicable	Diabetes Mellitus, Type 2	-	Sitagliptin	fithnydrwy(nhyxbsxprr) = swvncswdmx pmsocfhqhl (rneudhleys, -2.20 to -1.86)	Negative	03 Nov 2022
				Glimepiride	fithnydrwy(nhyxbsxprr) = oeluonmxwd pmsocfhqhl (rneudhleys, -2.08 to -1.75)
NCT03703869 (ATOS, EASD2022)	Not Applicable	Diabetes Mellitus, Type 2	3,651	insulin glargine 300 U/mL (No/minimal titration (0-2 U))	issakggpjr(zqnoxjexuh) = kbujdzitch tjvjsgfpwb (qmmpicbcoi ) View more	Positive	20 Sep 2022
				insulin glargine 300 U/mL (2-6 U)	issakggpjr(zqnoxjexuh) = abtlnxvbzy tjvjsgfpwb (qmmpicbcoi ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis